C07K 14/07
Vaccinia virus
Official title: Vaccinia virus; Variola virus
C07K14/07 (Vaccinia virus) appears on 18 US grants and 27 published applications in this corpus.
Search patents in C07K- Granted patents
- 18
- Published applications
- 27
- Assignees
- 12
- Inventors
- 28
- Latest grant
- 11 Mar 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 1 | 0 |
| 2012 | 0 | 0 |
| 2013 | 1 | 5 |
| 2014 | 1 | 1 |
| 2015 | 6 | 1 |
| 2016 | 0 | 1 |
| 2017 | 1 | 2 |
| 2018 | 3 | 1 |
| 2019 | 0 | 2 |
| 2020 | 0 | 2 |
| 2021 | 1 | 3 |
| 2022 | 1 | 2 |
| 2023 | 2 | 1 |
| 2024 | 0 | 2 |
| 2025 | 1 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Oncolytic viruses targeting STAT311 Mar 2025US 12,246,049 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Glycotargeting therapeutics24 Oct 2023US 11,793,882 B2Ecole Polytechnique Federale De Lausanne (Epfl)
- Compositions and methods of interferon alpha binding proteins4 Jul 2023US 11,690,895 B2Meiogen Biotechnology Corporation
- Oncolytic viruses targeting STAT322 Feb 2022US 11,253,559 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Glycotargeting therapeutics9 Mar 2021US 10,940,209 B2Ecole Polytechnique Federale De Lausanne (Epfl)
- Glycotargeting therapeutics30 Apr 2026US 2026/0115300 A1Ecole Polytechnique Federale De Lausanne (Epfl)
- Oncolytic virus and uses thereof29 Feb 2024US 2024/0067936 A1Sillajen, Inc.
- Oncolytic viruses targeting stat318 Jan 2024US 2024/0016865 A1University of Pittsburgh - of the Commonwealth Ststem of Higher Education
- Glycotargeting therapeutics13 Apr 2023US 2023/0115331 A1Ecole Polytechnique Federale De Lausanne (Epfl)
- Oncolytic viruses targeting stat35 May 2022US 2022/0133824 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
Most cited
By later US patents
- Glycotargeting therapeutics16US 10,046,056 B2Ecole Polytechnique Federale De Lausanne (Epfl) · 2018
- Glycotargeting therapeutics9US 10,940,209 B2Ecole Polytechnique Federale De Lausanne (Epfl) · 2021
- Immunoregulatory peptides and methods of use4US 8,450,285 B213Therapeutics, Inc. · 2013
- Generation of new pancreatic beta cells2US 9,133,440 B22015
- Glycotargeting therapeutics1US 11,793,882 B2Ecole Polytechnique Federale De Lausanne (Epfl) · 2023